335
Views
20
CrossRef citations to date
0
Altmetric
Review

Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways

&
Pages 203-215 | Published online: 06 Aug 2014

Figures & data

Figure 1 Frequencies of genetic lesions identified in primary breast tumors.

Notes: The percentages of tumors exhibiting mutations, amplifications, or homozygous deletions of genes in the PI3K/AKT/mTOR and CDK4/6 pathways are indicated. Data from the TCGA dataset containing molecular subtyping data of 515 breast tumorsCitation16 were extracted and used to generate an oncoprint plot using the cBio Cancer Genomics Portal.Citation155,Citation156 The results published here are in whole or part based upon data generated by the TCGA Research Network (http://cancergenome.nih.gov/).
Abbreviations: HER2, human epidermal growth factor receptor 2; C-L, claudin-low; PI3K, phosphoinositide 3-kinase; EGFR, epidermal growth factor receptor; IGF-1R, insulin-like growth factor-1 receptor; InsR, insulin receptor; CDK, cyclin-dependent kinase; CCND, cyclin D; mTOR, mammalian target of rapamycin; TCGA, The Cancer Genome Atlas; PTEN, phosphatase and tensin homolog.
Figure 1 Frequencies of genetic lesions identified in primary breast tumors.

Table 1 Clinical development status of targeted therapeutics in breast cancer